Action·LSE·£
Adicet Bio, Inc., a pioneering biotechnology firm, is dedicated to the discovery and development of "off-the-shelf" gamma delta T cell therapies aimed at combating cancer and other illnesses. Their innovative approach involves genetically modifying gamma delta T cells by integrating both chimeric antigen receptors (CARs) and T-cell receptor-mimicking antibodies. This proprietary engineering is designed to achieve highly selective tumor targeting, bolster both innate and adaptive anti-tumor immune responses, and enhance cell persistence for durable therapeutic outcomes in patients. Their lead therapeutic candidate, ADI-001, is currently progressing through Phase I clinical trials as a potential treatment for non-Hodgkin's lymphoma. Furthermore, their pipeline includes ADI-002, currently undergoing preclinical studies for various solid tumors. The company operates out of Boston, Massachusetts.
Voyez le prix de 0HX7.L en direct sur votre écran physique. Alertes via apps iOS et Android.
